Fludarabine/full dose i.v. busulfan conditioning regimen in allogeneic PBSC transplantation for high risk patients

被引：0
|
作者：
Chunduri, S. [1 ]
Dobogai, L. C. [1 ]
Peace, D. [1 ]
Saunthararajah, Y. [1 ]
Quigley, J. [1 ]
Chen, Y. -H. [1 ]
Boccuni, P. [1 ]
Hoffman, R. [1 ]
Mahmud, N. [1 ]
Beri, R. [1 ]
Hurter, E. [1 ]
Rondelli, D. [1 ]
机构：
[1] Univ Illinois, Hematol Oncol Sect, Chicago, IL USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2007年 / 13卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2006.12.235
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
230
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [1] Comparable toxicity between Fludarabine/full dose i.v. Busulfan and fludarabine/melphalan in allogeneic PBSC transplantation.
    Chunduri, S
    Jessop, E
    Dobogai, LC
    Peace, D
    Saunthararajah, Y
    Chen, YH
    Mahmud, N
    Maynard, V
    Hoffman, R
    Rondelli, D
    BLOOD, 2004, 104 (11) : 340B - 341B
  • [2] Can we consider fludarabine full dose i.v. busulfan a reduced intensity conditioning regimen?
    Chunduri, S
    Jessop, E
    Dobogai, L
    Peace, D
    Saunthararajah, Y
    Chen, YH
    Mahmud, N
    Maynard, V
    Hoffman, R
    Rondelli, D
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 25 - 26
  • [3] High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen
    Geddes, Michelle
    Kangarloo, S. Bill
    Naveed, Farrukh
    Quinlan, Diana
    Chaudhry, M. Ahsan
    Stewart, Douglas
    Savoie, M. Lynn
    Bahlis, Nizar J.
    Brown, Christopher
    Storek, Jan
    Andersson, Borje S.
    Russell, James A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 220 - 228
  • [4] Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients
    Iravani, M.
    Evazi, M. R.
    Mousavi, S. A.
    Shamshiri, A. R.
    Tavakoli, M.
    Ashouri, A.
    Samiee, S.
    Chahardovali, B.
    Alimoghaddam, K.
    Ghaffari, S. H.
    Ghavamzadeh, A.
    BONE MARROW TRANSPLANTATION, 2007, 40 (02) : 105 - 110
  • [5] Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients
    M Iravani
    M R Evazi
    S A Mousavi
    A R Shamshiri
    M Tavakoli
    A Ashouri
    S Samiee
    B Chahardovali
    K Alimoghaddam
    S H Ghaffari
    A Ghavamzadeh
    Bone Marrow Transplantation, 2007, 40 : 105 - 110
  • [6] Efficacy of treosulfan in combination with fludarabine as conditioning regimen in allogeneic transplantation as compared with a myeloablative conditioning using busulfan and fludarabine
    Calvo Sanchez, J. A.
    Fernandez Garcia, S.
    Aranguren del Castillo, L.
    Fernandez-Luis, S.
    Yanez San Segundo, L.
    Insunza Gaminde, A.
    Fernandez Escalada, N.
    Martin Sanchez, G.
    Colorado Araujo, M. M.
    Lopez Duarte, M.
    Sanchez Escamilla, M.
    Montes Gaisan, C.
    Romon Alonso, J. I.
    Arroyo Rodriguez, J. L.
    Ocio San Miguel, E. M.
    Bermudez Rodriguez, M. A.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 166 - 167
  • [7] Phase I study of myeloablative conditioning regimen of full-dose busulfan, melphalan, and fludarabine for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed aggressive lymphoma
    Koji, I.
    Hisashi, Y.
    Go, Y.
    Daisuke, K.
    Kosei, K.
    Mitsuhiro, Y.
    Aya, N.
    Kazuya, I.
    Shinsuke, T.
    Yuki, A-M
    Naoyuki, U.
    Akiko, Y.
    Shigeyoshi, M.
    Shuichi, T.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S451 - S451
  • [8] Allogeneic bone marrow transplantation in patients with hematological malignancy using busulfan, thiotepa, fludarabine as conditioning regimen
    Raiola, A. M.
    Dominietto, A.
    Varaldo, R.
    Gualandi, F.
    Di Grazia, C.
    Lamparelli, T.
    Bregante, S.
    van Lin, M. T.
    Galaverna, F.
    Ghiso, A.
    Marani, C.
    Bacigalupo, A.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S221 - S221
  • [9] Allogeneic PBSC transplantation after non-myeloablative regimen containing busulfan, fludarabine, and ATG.
    Mayer, J
    Krahulová, M
    Korístek, Z
    Vorlícek, J
    BONE MARROW TRANSPLANTATION, 1999, 23 : S23 - S23
  • [10] Fludarabine, busulfan, and thiotepa may be a promising conditioning regimen for myelofibrosis patients undergoing allogeneic stem cell transplantation
    Shouval, Roni
    Vega, Yakov
    Fein, Joshua A.
    Danylesko, Ivetta
    Tov, Noga Shem
    Yerushalmi, Ronit
    Nagler, Arnon
    Shimoni, Avichai
    BONE MARROW TRANSPLANTATION, 2019, 54 : 204 - 205
12345